Innocare Optoelectronics Corp. (6861) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Innocare Optoelectronics Corp. stock TWD 178, price TWD 174, upside +2.4%, quality 65 out of 100. Rating: fairly valued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
59‑month range 39.68 TWD – 458.96 TWD · fair‑value band 126.54 TWD – 230.88 TWD · the 173.50 TWD price screens below the 177.60 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow Innocare Optoelectronics in your weekly email
Every Wednesday you see whether Innocare Optoelectronics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
InnoCare Optoelectronics Corporation engages in the design, development, manufacture, and sale of optical instruments and medical devices. It also offers X-ray flat panel detectors sensors for healthcare, veterinary, security, and industrial applications in Taiwan and internationally.
Show moreShow less
It offers thin film transistors and scintillators, and other medical products, as well as accessories, including power and ethernet cables, charger sets, and batteries. InnoCare Optoelectronics Corporation was founded in 2019 and is headquartered in Tainan City, Taiwan.
Stock analysis
Innocare Optoelectronics Corp. (6861) currently trades at 173.50 TWD, while our model-based Fair Value estimate is 177.60 TWD, so the stock looks roughly fairly valued today (gap 2.3%).
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 101.73 TWD per share, and 0 of the 26 models we run sit above the 173.50 TWD price.
Bear case: the Asset-Based group reads lowest at 27.77 TWD, and 26 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: 126.54 TWD (bear) to 230.88 TWD (bull), the price of 173.50 TWD sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 65/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak: less than 2 % a year.
Innocare Optoelectronics Corp. reported revenue of 2.3B TWD in FY2025 versus 1.9B TWD in FY2021, a compound +4.3%/yr. Reported net income was 160M TWD in FY2025, compounding −5.3%/yr from FY2021.
Key figures
Market cap 7.0B TWD (≈ $213M) Micro · P/E ratio 27.5 · P/S ratio 2.54 · EPS (TTM) 6.30 TWD · Dividend yield 1.2% · Net margin 9.8% · Return on equity 18.5% · Return on assets (EBIT) 6.8% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 56 out of 100 (low confidence).
What moves the price
The share trades about 62% below its 52-week high and 211% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −15% fair-value upside, at 2%, 6861 screens cheaper than that median.
Fair Value models
Bear126.54 TWDFair Value 177.60 TWDBull230.88 TWD
Price 173.50 TWD · Upside +2.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (3.69 TWD per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
+15.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.4%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+32.1%
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−4.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year−6.0%
Dividend (yield on the price)1.2%
Profit margin 2019 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.20% → 6%
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+25.9%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Taiwan: IMF forecast 1.6% a year to 2030, 1.5% from 2016 to 2025) that is about +23.9% a year for the price.
News mood ⓘNews mood, the average tone of recent news (3 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.
Compare Innocare Optoelectronics Corp. with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 320 stocks
Beats the industry median on 8/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score65 · Above median
Fair Value upside+2.4% · Above median
Profitability
Return on equity (12 months)18.5% · Top 25%
Return on assets6.2% · Above median
Net margin (12 months)9.8% · Above median
Operating margin (12 months)12.6% · Above median
Growth and dividend
Revenue growth (quarter YoY)37.4% · Top 25%
Dividend yield (12 months)1.2% · Below median
Valuation Multiplesvs Medical Devices median · lower = cheaper
P/E (12 months)27.5× · Pricier than median
P/B4.81× · Priciest 25%
P/S (12 months)2.54× · Cheaper than median
Price / free cash flow (fiscal year)29.1× · Pricier than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Innocare Optoelectronics Corp. (6861) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of 177.60 TWD versus a price of 173.50 TWD, about +2% upside (fairly valued).
What is the fair value of 6861?
Our model-based fair value for Innocare Optoelectronics Corp. is 177.60 TWD (as of Nov 8, 2026), built from audited fundamentals. The current price: 173.50 TWD.
What is the quality score of 6861?
Innocare Optoelectronics Corp. has a Quality Score of 65/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Innocare Optoelectronics Corp. (6861)?
Our model-based price target is the fair value of 177.60 TWD (as of Nov 8, 2026) from 26 valuation models. Cautious scenario 126.54 TWD, optimistic scenario 230.88 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Innocare Optoelectronics Corp. stock forecast for 2026?
Our models put fair value at 177.60 TWD, about +2% upside versus a price of 173.50 TWD (fairly valued). Cautious scenario 126.54 TWD, optimistic scenario 230.88 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Innocare Optoelectronics Corp. (6861)?
Innocare Optoelectronics Corp. reported trailing-twelve-month revenue of about 2.8B TWD (latest available figure, as of Nov 8, 2026).
Does Innocare Optoelectronics Corp. pay a dividend?
Innocare Optoelectronics Corp. currently shows a dividend yield of 1.15% relative to its recent price (as of Nov 8, 2026).
How much is the dividend of Innocare Optoelectronics Corp. (6861) and when is the ex-dividend date?
Innocare Optoelectronics Corp. pays a dividend of 2.00 TWD per share a year, a dividend yield of 1.2%. The last ex-dividend date was Jun 15, 2026. A dividend has been paid every year since at least 2022. The payout ratio is 31.7% of earnings. Free cash flow covers the dividend 2.89 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into Innocare Optoelectronics Corp. (6861)?
For today's price to be fair in a discounted-cash-flow model, Innocare Optoelectronics Corp. would have to grow free cash flow by +25.9 % per year for five years (discount rate 14.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -0.4 % per year. As of Nov 8, 2026.
What discount rate (WACC) does the fair value of 6861 use?
Our models discount Innocare Optoelectronics Corp. at 14.3 %: a base by market capitalisation (small), damped by beta 2.24, country premium for Taiwan. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Innocare Optoelectronics Corp. that is +25.9 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (14.3 %) and the same formula as our fair value.
How much growth has Innocare Optoelectronics Corp. (6861) delivered so far?
Over the past 5 years revenue at Innocare Optoelectronics Corp. grew -0.4 % a year. The price currently implies free-cash-flow growth of +25.9 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Innocare Optoelectronics Corp. (6861) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Innocare Optoelectronics Corp. (+25.9 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Innocare Optoelectronics Corp. (6861)?
The free-cash-flow yield on the price is 3.33 %: that much free cash flow Innocare Optoelectronics Corp. produces per unit of market value. When it exceeds the discount rate of our models (14.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Innocare Optoelectronics Corp. (6861)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Innocare Optoelectronics Corp. it is 177.60 TWD per share (as of Nov 8, 2026), against a price of 173.50 TWD. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Innocare Optoelectronics Corp. stock overvalued or undervalued in 2026?
As of Nov 8, 2026, 6861 trades below its calculated fair value: price 173.50 TWD, fair value 177.60 TWD, a gap of about +2% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6861?
No. The price is what the market pays today (173.50 TWD); the fair value is what the company's own numbers justify (177.60 TWD). For Innocare Optoelectronics Corp. the two are 4.10 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Innocare Optoelectronics Corp. worth?
The market values Innocare Optoelectronics Corp. at about 7.0B TWD (market capitalisation, as of Nov 8, 2026). Per share that is 173.50 TWD; our models calculate a fair value of 177.60 TWD per share.
What do the bullish and bearish scenarios say about 6861?
Our models span a range for Innocare Optoelectronics Corp.: cautious scenario 126.54 TWD, base 177.60 TWD, optimistic 230.88 TWD per share (as of Nov 8, 2026, price 173.50 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 6861?
Innocare Optoelectronics Corp. trades at a price-to-earnings ratio of 27.5 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 177.60 TWD is built from several models across several years. Median P/E at fiscal year-end, 5 fiscal years (2021 to 2025), reported earnings: 16.8. Other multiples: P/B 4.8, P/S 2.5, EV/EBITDA 20.1.
How solid is the balance sheet of Innocare Optoelectronics Corp. (6861)?
Balance-sheet figures for Innocare Optoelectronics Corp. (as of Nov 8, 2026): return on equity 18.5%. They feed the Quality Score of 65/100, which measures business quality independently of the share price.
How far is 6861 from its 52-week high?
Innocare Optoelectronics Corp. trades at 173.50 TWD, about 62% below its 52-week high of 458.96 TWD and 211% above the low of 55.83 TWD (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 177.60 TWD is for.
Which stocks are comparable to Innocare Optoelectronics Corp.?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Innocare Optoelectronics Corp. stock attractive at the current price?
The data as of Nov 8, 2026: price 173.50 TWD, calculated fair value 177.60 TWD (+2%), Quality Score 65/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6861 calculated?
We run Innocare Optoelectronics Corp. through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 177.60 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Innocare Optoelectronics Corp. currently trades 2% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Innocare Optoelectronics Corp. (6861)?
The closing price on Nov 6, 2026 was 173.50 TWD. Our model-based fair value is 177.60 TWD, about +2% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Innocare Optoelectronics Corp. right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (126.54 TWD to 230.88 TWD) leaves room in how you read the outcome.
Key figures of Innocare Optoelectronics Corp.
How large is the market capitalisation of Innocare Optoelectronics Corp. (6861)?
The market capitalisation of Innocare Optoelectronics Corp. is 7.0B TWD (≈ $213M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Innocare Optoelectronics Corp. (6861)?
The price-to-sales ratio of Innocare Optoelectronics Corp. is 2.54 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Innocare Optoelectronics Corp. (6861)?
Earnings per share at Innocare Optoelectronics Corp. are 6.30 TWD (price ÷ EPS = P/E 27.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Innocare Optoelectronics Corp. (6861)?
The dividend yield of Innocare Optoelectronics Corp. is 1.2% (payout 31.7%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Innocare Optoelectronics Corp. (6861)?
The net margin of Innocare Optoelectronics Corp. is 9.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Innocare Optoelectronics Corp. (6861)?
The return on equity (ROE) of Innocare Optoelectronics Corp. is 18.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Innocare Optoelectronics Corp. (6861)?
On an EBIT basis the return on assets of Innocare Optoelectronics Corp. is 6.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Innocare Optoelectronics Corp. (6861)?
The operating margin of Innocare Optoelectronics Corp. is 12.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Innocare Optoelectronics Corp. (6861)?
Revenue at Innocare Optoelectronics Corp. is growing +37.4% versus a year earlier (3y avg +6.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Innocare Optoelectronics Corp. (6861)?
Earnings per share at Innocare Optoelectronics Corp. are growing +203% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Innocare Optoelectronics Corp. (6861) hold?
Innocare Optoelectronics Corp. holds more cash than debt, 734M TWD net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Innocare Optoelectronics Corp. in the live analysis
One click puts Innocare Optoelectronics Corp. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 8, 2026